STRO NASDAQ
Sutro Biopharma, Inc.
1W: -23.1%
1M: -44.7%
3M: -62.0%
YTD: -19.1%
1Y: -15.5%
3Y: -72.2%
5Y: -95.3%
$8.87
-0.01 (-0.17%)
Weekly Expected Move ±12.7%
$7
$8
$9
$11
$12
Credit Risk of going bust: higher than 69% of companies Debt: 6.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.11 (down 99%), Sutro Biopharma, Inc. would be worth roughly what it owes.
Total debt $10.8M against a stock market value of $147.1M.
Distance to default 3.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.4M (short-term plus half of long-term), stock volatility 88.8%; Altman Z'' -18.77. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.11 (down 99%), Sutro Biopharma, Inc. would be worth roughly what it owes.
Total debt $10.8M against a stock market value of $147.1M.
Distance to default 3.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.4M (short-term plus half of long-term), stock volatility 88.8%; Altman Z'' -18.77. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
20 relationships17
As Filer
counterparties named
3
As Counterparty
mentioned by others
4
Rel. Types
2021-10-12
Earliest Filing
2024-04-02
Latest Filing
partner: 13
licensee: 2
investor: 1
acquirer: 1
Counterparties (Filed by STRO)
17 relationshipsCompanies named in STRO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Ipsen Pharma SAS | — | partner | Exclusive global license agreement for STRO-003 | 2024-04-02 | View |
| Ipsen Biopharmaceuticals, Inc. (USA) | — | investor | Purchased 4,827,373 shares of common stock for $25 million | 2024-04-02 | View |
| Vaxcyte, Inc. | PCVX | partner | Entered into an Option Agreement and Manufacturing Rights Agreement for exclusive manufacturing rights and license of ex | 2023-11-27 | View |
| Vaxcyte, Inc. | PCVX | partner | License agreement amendment regarding cell-free extract manufacturing rights and royalty terms | 2023-10-04 | View |
| Blackstone Life Sciences | BX | acquirer | Acquired 4% royalty interest in Vaxcyte products from Sutro Biopharma | 2023-06-26 | View |
| Vaxcyte Inc. | PCVX | partner | Original licensee of Sutro Biopharma's vaccine technology | 2023-06-26 | View |
| Vaxcyte, Inc. | PCVX | partner | Sutro Biopharma granted Vaxcyte authorization to source cell-free extract from an alternate CMO and an option to manufac | 2022-12-20 | View |
| Astellas Pharma Inc. | — | partner | License and Collaboration Agreement for immunostimulatory antibody-drug conjugates | 2022-06-28 | View |
| Bristol Myers Squibb | CELG-RI | partner | Strategic collaboration partner | 2022-06-28 | View |
| Merck | MRK | partner | Strategic collaboration partner | 2022-06-28 | View |
| EMD Serono | — | partner | Strategic collaboration partner | 2022-06-28 | View |
| Tasly | — | partner | Greater China deal for STRO-002 | 2022-06-28 | View |
| BioNova | — | partner | Greater China deal for STRO-001 | 2022-06-28 | View |
| Vaxcyte | PCVX | partner | Collaboration for VX-24 vaccine development | 2022-06-28 | View |
| Tasly Biopharmaceuticals Co., Ltd. | — | licensee | Exclusive license to develop and commercialize STRO-002 in Greater China | 2022-04-20 | View |
| Tasly Biopharmaceuticals Co., Ltd. | — | licensee | Exclusive license agreement for STRO-002 development and commercialization in Greater China. | 2021-12-27 | View |
| BioNova Pharmaceuticals Limited | — | partner | Sutro Biopharma granted BioNova an exclusive option to develop and commercialize STRO-001 in Greater China. | 2021-10-12 | View |
Mentioned As Counterparty
3 mentionsOther companies that named STRO in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| PCVX Vaxcyte, Inc. | partner | Vaxcyte exercised an option to acquire manufacturing rights and exclusive rights to Sutro's cell-free extract technology | 2023-11-27 | View |
| PCVX Vaxcyte, Inc. | partner | Vaxcyte entered into an option grant agreement and amended a license agreement with Sutro regarding cell-free extract ma | 2023-10-04 | View |
| PCVX Vaxcyte, Inc. | partner | Vaxcyte entered into an option grant agreement to acquire authorization and rights to source Sutro's cell-free extract a | 2022-12-20 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-12 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-06-08 | Shareholder Vote | View | |
| 2026-05-14 | Earnings Release; Exhibits | View | |
| 2026-03-23 | Termination of Agreement; Earnings Release; Exhibits | View | |
| 2026-02-10 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-12-17 | Other Events | View | |
| 2025-12-03 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-29 | Costs Associated with Exit or Disposal Activities; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-25 | Notice of Delisting or Transfer | View | |
| 2025-06-10 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-02 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-14 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-03-13 | Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities; De | View | |
| 2024-12-10 | Other Events | View | |
| 2024-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-12 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR